Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Anti-idiotype vaccines for human follicular lymphoma

Leukemia volume 14, pages 1333–1339 (2000)Cite this article

Abstract

Cancer vaccines are conceived as therapeutic tools, in contrast to the prophylactic vaccines that have resolved the problem of a number of infectious diseases in a highly cost-effective way. Over the last decade, anti-idiotype vaccines for human follicular lymphoma have started to come into their own. Whereas 10 years ago it was not even known whether patients could be immunized against an antigen of their own tumor, a phase III clinical trial based on this finding is now already underway. The rapidity of this development encourages the hope that active immunotherapy may become decisive in oncology sooner than expected. Many important results have already been achieved. These include evidence of vaccine-induced, tumor-specific humoral and cellular responses along with the first documented molecular remissions following vaccination. Crucial questions still awaiting an answer include: do Id vaccines actually cure at least a fraction of FL patients? What is the most effective vaccine formulation? Is it possible to reduce the workload involved in producing an effective Id vaccine?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Abbas AK, Lichtman AH, Pober JS . Cellular and Molecular Immunology (3rd edn) Saunders: Philadelphia 1997

    Google Scholar 

  2. Paul WE . Fundamental Immunology (4th edn) Lippincott: Philadelphia 1999

    Google Scholar 

  3. Jerne NK . Towards a network theory of the immune system Ann Immunol 1974 125C: 373–389

    CAS  Google Scholar 

  4. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A . Tumor antigens recognized by T lymphocytes Annu Rev Immunol 1994 12: 337–365

    CAS  PubMed  Google Scholar 

  5. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W . Immunity to oncogenic proteins Immunol Rev 1995 145: 33–59

    CAS  PubMed  Google Scholar 

  6. Henderson RA, Finn OJ . Human tumor antigens are ready to fly Adv Immunol 1996 62: 217–256

    CAS  PubMed  Google Scholar 

  7. Syrengelas AD, Levy R . DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection J Immunol 1999 162: 4790–4795

    CAS  PubMed  Google Scholar 

  8. Schultze JL, Nadler LM . T cell mediated immunotherapy for B cell lymphoma J Mol Med 1999 77: 322–331

    CAS  PubMed  Google Scholar 

  9. Raffeld M, Neckers L, Longo DL, Cossman J . Spontaneous alteration of idiotype in a monoclonal B cell lymphoma. Escape from detection by anti-idiotype New Engl J Med 1985 312: 1653–1658

    CAS  PubMed  Google Scholar 

  10. Meeker T, Lowder J, Cleary ML, Stewart S, Warnke R, Sklar J, Levy R . Emergence of idiotype variants during treatment of B cell lymphoma with anti-idiotype antibodies New Engl J Med 1985 312: 1658–1665

    CAS  PubMed  Google Scholar 

  11. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R . Tumor-specific idiotype vaccines in the treatment of patients with B cell lymphoma – long-term results of a clinical trial Blood 1997 89: 3129–3135

    CAS  PubMed  Google Scholar 

  12. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW . Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma Nature Med 1999 5: 1171–1177

    CAS  PubMed  Google Scholar 

  13. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM . In vivo expression of B7–1 and B7–2 by follicular lymphoma cells can prevent induction of T cell anergy but is insufficient to induce significant T cell proliferation Blood 1997 90: 4297–4306

    CAS  PubMed  Google Scholar 

  14. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R . Induction of immune responses in patients with B cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors New Engl J Med 1992 327: 1209–1215

    CAS  PubMed  Google Scholar 

  15. George AJ, Stevenson FK . Prospects for the treatment of B cell tumors using idiotypic vaccination Int Rev Immunol 1989 4: 271–310

    CAS  PubMed  Google Scholar 

  16. Levy R, Miller RA . Therapy of lymphoma directed at idiotypes J Natl Cancer Inst Monogr 1990 10: 61–68

    Google Scholar 

  17. Sirisinha S, Eisen HN . Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins Proc Natl Acad Sci USA 1971 68: 3130–3135

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN . Myeloma proteins as tumor-specific transplantation antigens Proc Natl Acad Sci USA 1972 69: 1540–1544

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL . Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor Lancet 1995 345: 1016–1020

    CAS  PubMed  Google Scholar 

  20. Bergenbrant S, Yi Q, Osterborg A, Bjorkholm M, Osby E, Mellstedt H, Lefvert AK, Holm G . Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients Br J Haematol 1996 92: 840–846

    CAS  PubMed  Google Scholar 

  21. Osterborg A, Yi Q, Henriksson L, Fagerberg J, Bergenbrant S, Jeddi-Tehrani M, Ruden U, Lefvert AK, Holm G, Mellstedt H . Idiotype immunization combined with granulocyte–macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T cell responses Blood 1998 91: 2459–2466

    CAS  PubMed  Google Scholar 

  22. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R . Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study Blood 1999 93: 2411–2419

    CAS  PubMed  Google Scholar 

  23. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S, Stiefel T, Even J, Novero D, Boccadoro M, Pileri A . Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy Blood 1999 94: 673–683

    CAS  PubMed  Google Scholar 

  24. Lim SH, Bailey-Wood R . Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma Int J Cancer 1999 83: 215–222

    CAS  PubMed  Google Scholar 

  25. Campbell MJ, Carroll W, Kon S, Thielemans K, Rothbard JB, Levy S, Levy R . Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits J Immunol 1987 139: 2825–2833

    CAS  PubMed  Google Scholar 

  26. Campbell MJ, Esserman L, Levy R . Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide J Immunol 1988 141: 3227–3233

    CAS  PubMed  Google Scholar 

  27. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC . A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 1994 84: 1361–1392

    CAS  PubMed  Google Scholar 

  28. Horning SJ, Rosenberg SA . The natural history of initially untreated low-grade non-Hodgkin's lymphomas New Engl J Med 1984 311: 1471–1475

    CAS  PubMed  Google Scholar 

  29. Bendandi M, Longo DL . Biologic therapy for lymphoma Curr Opin Oncol 1999 11: 343–350

    CAS  PubMed  Google Scholar 

  30. Brown S, Dilley J, Levy R . Immunoglobulin secretion by mouse X human hybridomas: an approach for the production of anti-idiotype reagents useful monitoring patients with B cell lymphoma J Immunol 1980 125: 1037–1043

    CAS  PubMed  Google Scholar 

  31. Kobrin CB, Kwak LW . Development of vaccine strategies for the treatment of B cell malignancies Cancer Invest 1997 15: 577–587

    CAS  PubMed  Google Scholar 

  32. Kaminski MS, Kitamura K, Maloney DG, Levy R . Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein J Immunol 1987 138: 1289–1296

    CAS  PubMed  Google Scholar 

  33. Sallusto F, Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med 1994 179: 1109–1118

    CAS  PubMed  Google Scholar 

  34. Kwak LW, Young HA, Pennington RW, Weeks SD . Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T cell response Proc Natl Acad Sci USA 1996 93: 10972–10977

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA . Granulocyte–macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines Blood 1996 88: 202–210

    CAS  PubMed  Google Scholar 

  36. de Gruijl TD, Curiel DT . Cancer vaccine strategies get bigger and better Nature Med 1999 5: 1124–1125

    CAS  PubMed  Google Scholar 

  37. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE . Idiotypic DNA vaccines against B cell lymphoma Immunol Rev 1995 145: 211–228

    CAS  PubMed  Google Scholar 

  38. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK . Idiotypic vaccination against human B cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines Blood 1994 83: 3279–3288

    CAS  PubMed  Google Scholar 

  39. Stevenson FK . Vaccine Strategies in Indolent Lymphoma. Education Program Book ASH: Washington 1999

    Google Scholar 

  40. Sugai S, Palmer DW, Talal N, Witz IP . Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice J Exp Med 1974 140: 1547–1558

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Freedman PM, Autry JR, Tokuda S, Williams RC Jr . Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein J Natl Cancer Inst 1976 56: 735–740

    CAS  PubMed  Google Scholar 

  42. Stevenson FK, Gordon J . Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation J Immunol 1983 130: 970–973

    CAS  PubMed  Google Scholar 

  43. George AJ, Tutt AL, Stevenson FK . Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1 J Immunol 1987 138: 628–634

    CAS  PubMed  Google Scholar 

  44. Carroll WL, Thielemans K, Dilley J, Levy R . Mouse x human heterohybridomas as fusion partners with human B cell tumors J Immunol Meth 1986 89: 61–72

    CAS  Google Scholar 

  45. Tao MH, Levy R . Idiotype/granulocyte–macrophage colony-stimulating factor fusion protein as a vaccine for B cell lymphoma Nature 1993 362: 755–758

    CAS  PubMed  Google Scholar 

  46. Syrengelas AD, Chen TT, Levy R . DNA immunization induces protective immunity against B cell lymphoma Nature Med 1996 2: 1038–1041

    CAS  PubMed  Google Scholar 

  47. Spellerberg MB, Zhu D, Thompsett A, King CA, Hamblin TJ, Stevenson FK . DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C J Immunol 1997 159: 1885–1892

    CAS  PubMed  Google Scholar 

  48. King CA, Spellerberg MB, Zhu D, Rice J, Sahota SS, Thompsett AR, Hamblin TJ, Radl J, Stevenson FK . DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma Nature Med 1998 4: 1281–1286

    CAS  PubMed  Google Scholar 

  49. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW . Genetic fusion of chemokines to a self tumor antigen induces protective, T cell-dependent antitumor immunity Nat Biotechnol 1999 17: 253–258

    CAS  PubMed  Google Scholar 

  50. McCormick AA, Kumagai MH, Hanley K, Turpen TH, Hakim I, Grill LK, Tuse D, Levy S, Levy R . Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants Proc Natl Acad Sci USA 1999 96: 703–708

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, Skerra A, Veelken H . Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination J Immunol Meth 1999 229: 141–153

    CAS  Google Scholar 

  52. Mocikat R, Selmayr M, Thierfelder S, Lindhofer H . Trioma-based vaccination against B cell lymphoma confers long-lasting tumor immunity Cancer Res 1997 57: 2346–2349

    CAS  PubMed  Google Scholar 

  53. Strehl J, Selmayr M, Kremer JP, Hultner L, Lindhofer H, Mocikat R . Gene therapy of B cell lymphoma with cytokine gene-modified trioma cells Int J Cancer 1999 83: 113–120

    CAS  PubMed  Google Scholar 

  54. Allison AC, Byars NE . An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity J Immunol Meth 1986 95: 157–168

    CAS  Google Scholar 

  55. Nelson EL, Li X, Hsu FJ, Kwak LW, Levy R, Clayberger C, Krensky AM . Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B cell, non-Hodgkin's lymphoma Blood 1996 88: 580–589

    CAS  PubMed  Google Scholar 

  56. Bendandi M, Kwak LW . Translational development of patient-specific vaccination for follicular lymphoma Haematologica 1999 84: S70–72

    Google Scholar 

  57. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D . Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Med 1998 4: 328–332

    CAS  PubMed  Google Scholar 

  58. Sallusto F, Lanzavecchia A . Mobilizing dendritic cells for tolerance, priming, and chronic inflammation J Exp Med 1999 189: 611–614

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R . Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells Nature Med 1996 2: 52–58

    CAS  PubMed  Google Scholar 

  60. Timmerman JM, Davis TA, Hsu FJ, Caspar CB, Benike C, Liles TM, Czerwinski DK, Taidi B, van Beckhoven A, Engleman EG, Levy R . Idiotype-pulsed dendritic cell vaccination for B cell lymphoma: clinical and immunological responses in 26 patients Blood 1999 94: (Suppl. 1) Abstr. 1712

    Google Scholar 

  61. Hsu FJ, Komarovskaya M, Song B, Doyon AG . Active immunotherapy of patients with lymphoma with sequential dendritic cell and protein/adjuvant idiotype vaccines Blood 1999 94: (Suppl. 1) Abstr. 1713

    Google Scholar 

  62. Hawkins RE, Russell SJ, Marcus R, Ashworth LJ, Brissnik J, Zhang J, Winter G, Bleehen NM, Shaw MM, Williamson L, Ouwehand W, Stevenson F, Hamblin TJ, Oscier D, Zhu D, King C, Kumar S, Thompsett A, Stevenson GT . A pilot study of idiotypic vaccination for follicular B cell lymphoma using a genetic approach. CRC NO: 92/33, protocol no: PH1/027 Hum Gene Ther 1997 8: 1287–1299

    CAS  PubMed  Google Scholar 

  63. Keating MJ . Purine analogs in the management of indolent lymphoproliferative disorders Haematologica 1999 84: S28–32

    Google Scholar 

  64. Maloney DG . Rituximab anti-CD20 antibody therapy of B-cell non-Hodgkin's lymphoma Haematologica 1999 84: S55–57

    Google Scholar 

  65. Press OW . Radioimmunotherapy of non-Hodgkin's lymphomas Haematologica 1999 84: S63–66

    Google Scholar 

  66. Gribben JG . Adoptive immunotherapy for B cell lymphoma Haematologica 1999 84: S67–69

    Google Scholar 

  67. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW . Immunization with granulocyte–macrophage colony-stimulating factor-transduced, but not B7–1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity J Immunol 1996 156: 3858–3865

    CAS  PubMed  Google Scholar 

  68. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM . Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity Proc Natl Acad Sci USA 1995 92: 8200–8204

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Caspar CB, Levy S, Levy R . Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations Blood 1997 90: 3699–3706

    CAS  PubMed  Google Scholar 

  70. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freeman G, Longtine JA, Pinkus GS, Nadler LM . All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275–3280

    CAS  PubMed  Google Scholar 

  71. Lopez-Guillermo A, Cabanillas F, McLaughlin P, Smith T, Hagemeister F, Rodriguez MA, Romaguera JE, Younes A, Sarris AH, Preti HA, Pugh W, Lee MS . The clinical significance of molecular response in indolent follicular lymphomas Blood 1998 91: 2955–2960

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Hematology and Medical Oncology, L e A Seragnoli, University of Bologna, Bologna, Italy

    M Bendandi

Authors
  1. M Bendandi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bendandi, M. Anti-idiotype vaccines for human follicular lymphoma. Leukemia 14, 1333–1339 (2000). https://doi.org/10.1038/sj.leu.2401861

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401861

Keywords

This article is cited by

Search

Advanced search

Quick links